## Connectivity guided EEG biofeedback as a treatment for Autistic disorders with and without seizures

Robert Coben, PhD Associate Fellow, EEG Biofeedback (BCIA) Diplomat, qEEG Certification Board Presented at the 2011 Autism One Annual Meeting Chicago, Illinois

### Connectivity theory of Autism



#### Connectivity theory of Autism

- Epigenetic etiology leading to neural inflammation.
   Genetic findings on chromosomes 16, 11, and 7q31 MET receptor tyrosine kinase.
   Neural connectivity anomalies underlicit he brain dysfunctions in autistic children.
- underlie the brain dysfunctions in autistic children. These neural connectivity disturbances lead to regional brain dysfunctions.
- Autistic children have overlapping neurophysiological dysfunctions.











Human EEG biofeedback was first attempted in the 1960s by Joe Kamiya at the University of Chicago. Early investigations focused on operant conditioning of alpha brain waves primarily to facilitate deep relaxation and meditation.

MR/beta biofeedback developed from operant conditioning of cats' EEG. Barry Sterman of UCLA serendiptilously discovered that when cats were exposed to toxic chemicals that usually induce epileptic setures, those who had been trained in the middle to high frequency range (12.20 kJr from a previous unrelated experiment had greater latency to seture onset, and a higher threshold for seture onset, than untrained cats. These results were replicated in monkeys and humans. The results with humans were subsequently replicated in some twelve research centers, comprising some twenty studies. After several years of treating patients with intractable setures with SMR biofeedback, it was noted that the hyperactive chiftern not only had decreased seizure activity, but their behavior improved as well.

In the mid 70's, Joel Lubar at the University of Tennessee examined the effect of neurofeedback on hyperactivity absent any seizure history.

## EEG biofeedback - Case 1 •

- 7 year old by diagnosed with PDD at the age of 5 Born 36 weeks gestation due to gestational diabetes with high liver enzymes
- Walked at 2 years and spoke in utternaces by 3 years
- . Difficulties with focusing,
- sitting still, temper outbursts, socialization, head banging, repetitive behaviors
- FSIQ = 80; Verbal IQ 75; Performance IQ = 90 Impairments in receptive language, motor sequencing, visual-perceptual analysis.
  - Unable to read or identify letters

an all has all to all an and all to	214 84 전 11 m 전 214 전 214 전 14	the Acad t & Contraction	went the second	
o many Moundary	hipphaminghr	humps	× 11.	
monthpurning	mouhommakp	hump		
· Mariaman mound	my had more more the	to monto to	×	
. in any million when	riphindration and for	Munner la	-	
- many many	mphannah	James and the	-	
· monormon	munhamman	adamana ana a	×	
a monterproperties a	and more thank the second s	mound a	× 11	
e annahananananan	when we are a second and the second	shymmetric a		
- month mound	mphanah	humple		
a ministranting	mohummuch	monto	×	
· March With Mary Mill	montermining	Homemon to	×	
· Wany WWW with	million have madely	have a	" Arten	
n mannahannan	whichmannth	from the for		
a malifolingermonia	man	de manuel a		1/
· management	monor manung	monto	× 0.	
· manhannymen	moundermanne	firming to	× 1	† 🤍 🗸
			allal a	Arging D.R.D.R.Bon
A family among the (a)				
matical - % the III Days bright to the same.				COMPARINE IN MARKING













# Efficacy of Connectivity Guided Neurofeedback for Autistic Spectrum Disorder: Controlled Analysis of 75 cases With a 1- to 2-year Follow-up



Robert Coben, PhD Presented at the 16<sup>th</sup> Annual ISNR Conference San Antonio, Texas August 30<sup>th</sup>, 2008

## Sample

- 110 subjects on the autistic spectrum, 85 in the experimental and 25 the control group.
- Age: mean = 9.72, sd = 3.1, range = 4 20.
  Medication: 77% none, 14% 1, 7% 2, 1% 3.
- Medication: 77% none, 14% 1, 7% 2, 1% 3.
  IQ: mean = 93, sd = 15.3, range = 50 130.
- IQ: mean = 93, sd = 15.3, range = 50 130.
  ATEC: mean = 50, sd = 13.4, range = 35 110.
- Arec: mean = 50, sd = 13.4, range = 35 110.
   Sessions: mean = 74.2, sd = 22.4, range = 40 170.
- No sign diff for age, gender, hand, race, meds, iq, atec.

		Sum of Squares	df	Mean Square	F	Sig.	
tecscchange	Between Groups	555.078	1	555.078	49.806	.000	3.7219e-010
	Within Groups	980.745	88	11.145			
	Total	1535.822	89	1070.057	70.764	0.00	
anecschange	Mithin Croups	1078.657		10/8.657	/6./54	.000	7.4479e-014
	Total	1205.298	00	13.697			
atersrarhanne	Retween Groups	020 970	1	626.976	41 606	000	
	Within Groups	1326.246	88	15.071			5.57368-009
	Total	1953.122	89				
atechpbchange	Between Groups	1519.036	1	1519.036	40.566	.000	840976-009
	Within Groups	3295.286	88	37.446			
	Total	4814.322	89				
atectotalchange	Between Groups	4242.801	1	14242.801	117.213	.000	7.3570e-018
	Within Groups	0693.022	88	121.512			
	Total	4935.822	89				











## Seizures in ASD



#### Paroxysmal discharges occur at even higher rates in ASD Spikes appear to reflect underlying intracranial foci, morphological brain abnormalities, and/or metabolic disturbances

# Regression in ASD

20 – 30% of all autistic children have a regression in speech or behavior early in IR (Canitalo, 2007) More severe symptomatology, speech and behavior The EEG is abnormal in a greater proportion of autistic children that regress Is regression associated with seizure disorders in ASD? Mixed findings: some show seizures to be related to regression and others do not. No other factor has been found to be related to EEG's are recommended in the evaluation of autistic disorders.

ł	Raw EE	G Wave	forms (	Longitu	udinal)			
*******	nass Annual	Eyer-Cloud 1771	162/162 176 (845 🕥	Segital Nov1/01	256 pb/sec	900 µMDN CENTRES	r .	2
644.67 67-33	ACC.		228	A				
13-76 78-64		-the		$\sim h$	Ac		<b>(</b>	
191.23 12.43		$\sim h$	~15					
012 12:01	- A	- Afr	AK		Í			
- 51-62 - 62-82		$\sim m$	22	2				
11.05		-th			1-		-	
PL.00				~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	m			
18.11	m	m		m	An			
16.62 80		- A	-h-	$\mathcal{M}$	Na		-	
	•							
	J H G H B I	DA RE	THE RECEIPTE	PE NE PE We	and a later	PERC OF	US THUNG	

N	lorm	al EC Ne	euroelectrie	c Eigenim	lage	
	Horizontal	N.7% Perception Constraints Co	23.4% (11)) (21))((21))((21)))((21))((21))((21))((21))((21))((21))((21))((21))((21))		377 5 <sup>0</sup> 0 0 0 0 0 0	
Eigenimages	Sagittal	6986	688	630	8-68 8-68	200
	Coronal	r" = 95.9%	r <sup>2</sup> = 95.2%	r <sup>2</sup> = 94.9%	r = 91.1%	с с с с с с с с с с с с с с с с с с с
	013-1	🎽 Delta	Theta	Alpha	Beta	Total

















		ANOVA				
		Sum of Squares	df	Mean Square	F	Sig.
SzchangePercent	Between Groups	1307.610	1	1307.610	1.566	.221
	Within Groups	23376.519	28	834.876		
	Total	24684.129	29			
ATECchangePercent	Between Groups	910.791	1	910.791	1.919	.193
	Within Groups	5220.841	11	474.622		
	20 A A	0101 000				
Interestina	Part: The	erapist v	12 ariabl	les and		
Interesting medication significantl	Part: The is do <mark>not</mark> i y.	erapist v influence	ariabl e the	les and results		

# Enduring effects of NF for ASD

- 20 patients with ASD seen for connectivity guided NF for at least 40 sessions and seen for follow-up assessment. Age: mean = 9.53, sd = 3.53, range = 5 - 20. Gender: 16 male, 4 female. General: 10 mare, 4 minute. Handedness: 16 right, 1 left, 3 mixed. Race: 100% Caucasian. Medications: 16 none, 11 med, 22 meds, 14 meds.
- NF Sessions: mean = 64.5, sd = 23.1.
- Follow-up period: mean = 10.1, sd = 4.8, range = 5 22months.

	Delet d Ca	males Test		
	Paired Sa	Imples lest		
		t	df	Sig. (2-tailed)
Pair 1	ATEC1 - ATEC2	11.302	19	.000
Pair 2	ATEC2 - ATEC3	.709	19	.487
Pair 3	BRIEF1 - BRIEF2	5.370	19	.000
Pair 4	BRIEF2 - BRIEF3	.193	19	.849
Pair 5	GADS1 - GADS2	8.332	19	.000
Pair 6	GADS2 - GADS3	.877	19	.392
Pair 7	PIC21 - PIC22	6.320	19	.000
Pair 8	PIC22 - PIC23	.326	19	.748
Pair 9	NPatexpre - NPatexpost	-5.297	19	.000
Pair 10	NPatexpost - NPatexfu	-3.021	19	.007
Pair 11	NPlangpre - NPlangpost	-2.235	10	.049
Pair 12	NPlangpost - NPlangfu	-2.347	10	.041
Pair 13	NPvppre - NPvppost	-5.308	18	.000
Pair 14	NPvppost - NPvpfu	-3.568	18	.002





#### EEG Biofeedback or Neurofeedback

98% of children with ASD improve with a full course of treatment. 91% lessen their symptoms by 30% or more. 0% worsen their condition or have long-lasting side effects. Worsen their condition or have long-lasting side effects.
 Average reduction in symptoms of 60 – 70%.
 Significant improvements in neuropsychological, language, social, and behavioral functions.
 Helps children at varied levels of functioning and intelligence levels (> IQ = 50) equally.
 Helps reduce seizure/parxysmal events in ASD with or without medication. Effects of treatment appear to be long-lasting and promote future developmental gains.

5